Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial
Abstract In the randomized, placebo-controlled PREVENT-19 phase 3 trial conducted in the U.S. and Mexico of the NVX-CoV2373 adjuvanted, recombinant spike protein nanoparticle vaccine, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks after two doses were assessed as correlates of risk and as correlates of protection against PCR-confirmed symptomatic SARS-CoV-2 infection (COVID- 19). These immune correlates analyses were conducted in the U.S. cohort of baseline SARS- CoV-2 negative per-protocol participants using a case-cohort design that measured the antibody markers from all 12 vaccine recipient breakthrough COVID-19 cases starting 7 days post antibody measurement and from 639 vaccine recipient non-cases (Mexico was excluded due to zero breakthrough cases with the efficacy data cut-off date April 19, 2021). In vaccine recipients, the baseline risk factor-adjusted hazard ratio of COVID-19 was 0.36 (95% CI: 0.20, 0.63), p<0.001 (adjusted p-0.005) per 10-fold increase in IgG spike concentration and 0.39 (0.19, 0.82), p=0.013 (adjusted p=0.030) per 10-fold increase in nAb ID50 titer. At spike IgG concentration 100, 1000, and 6934 binding antibody units/ml (100 is the 3rdpercentile, 6934 is the 97.5thpercentile), vaccine efficacy to reduce the probability of acquiring COVID-19 at 59 days post marker measurement was 65.5% (95% CI: 23.0%, 90.8%), 87.7% (77.7%, 94.4%), and 94.8% (88.0%, 97.9%), respectively. At nAb ID50 titers of 50, 100, 1000, and 7230 IU50/ml (50 is the 5thpercentile, 7230 the 97.5thpercentile), these estimates were 75.7% (49.8%, 93.2%), 81.7% (66.3%, 93.2%), 92.8% (85.1%, 97.4%) and 96.8% (88.3%, 99.3%). The same two antibody markers were assessed as immune correlates via the same study design and statistical analysis in the mRNA-1273 phase 3 COVE trial (except in COVE the markers were measured four weeks post dose two). Spike IgG levels were slightly lower and nAb ID50 titers slightly higher after NVX-CoV2373 than after mRNA-1273 vaccination. The strength of the nAb ID50 correlate was similar between the trials, whereas the spike IgG antibodies appeared to correlate more strongly with NVX-CoV2373 in PREVENT-19, as quantified by the hazard ratio and the degree of change in vaccine efficacy across antibody levels. However, the relatively few breakthrough cases in PREVENT-19 limited the ability to infer a stronger correlate. The conclusion is that both markers were consistent correlates of protection for the two vaccines, supporting potential cross-vaccine platform applications of these markers for guiding decisions about vaccine approval and use..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.06.22.22276362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI036358487 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI036358487 | ||
| 003 | DE-627 | ||
| 005 | 20240424104856.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220625s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.06.22.22276362 |2 doi | |
| 035 | |a (DE-627)XBI036358487 | ||
| 035 | |a (biorXiv)10.1101/2022.06.22.22276362 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fong, Youyi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immune Correlates Analysis of the PREVENT-19 COVID-19 Vaccine Efficacy Clinical Trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract In the randomized, placebo-controlled PREVENT-19 phase 3 trial conducted in the U.S. and Mexico of the NVX-CoV2373 adjuvanted, recombinant spike protein nanoparticle vaccine, anti-spike binding IgG concentration (spike IgG) and pseudovirus 50% neutralizing antibody titer (nAb ID50) measured two weeks after two doses were assessed as correlates of risk and as correlates of protection against PCR-confirmed symptomatic SARS-CoV-2 infection (COVID- 19). These immune correlates analyses were conducted in the U.S. cohort of baseline SARS- CoV-2 negative per-protocol participants using a case-cohort design that measured the antibody markers from all 12 vaccine recipient breakthrough COVID-19 cases starting 7 days post antibody measurement and from 639 vaccine recipient non-cases (Mexico was excluded due to zero breakthrough cases with the efficacy data cut-off date April 19, 2021). In vaccine recipients, the baseline risk factor-adjusted hazard ratio of COVID-19 was 0.36 (95% CI: 0.20, 0.63), p<0.001 (adjusted p-0.005) per 10-fold increase in IgG spike concentration and 0.39 (0.19, 0.82), p=0.013 (adjusted p=0.030) per 10-fold increase in nAb ID50 titer. At spike IgG concentration 100, 1000, and 6934 binding antibody units/ml (100 is the 3rdpercentile, 6934 is the 97.5thpercentile), vaccine efficacy to reduce the probability of acquiring COVID-19 at 59 days post marker measurement was 65.5% (95% CI: 23.0%, 90.8%), 87.7% (77.7%, 94.4%), and 94.8% (88.0%, 97.9%), respectively. At nAb ID50 titers of 50, 100, 1000, and 7230 IU50/ml (50 is the 5thpercentile, 7230 the 97.5thpercentile), these estimates were 75.7% (49.8%, 93.2%), 81.7% (66.3%, 93.2%), 92.8% (85.1%, 97.4%) and 96.8% (88.3%, 99.3%). The same two antibody markers were assessed as immune correlates via the same study design and statistical analysis in the mRNA-1273 phase 3 COVE trial (except in COVE the markers were measured four weeks post dose two). Spike IgG levels were slightly lower and nAb ID50 titers slightly higher after NVX-CoV2373 than after mRNA-1273 vaccination. The strength of the nAb ID50 correlate was similar between the trials, whereas the spike IgG antibodies appeared to correlate more strongly with NVX-CoV2373 in PREVENT-19, as quantified by the hazard ratio and the degree of change in vaccine efficacy across antibody levels. However, the relatively few breakthrough cases in PREVENT-19 limited the ability to infer a stronger correlate. The conclusion is that both markers were consistent correlates of protection for the two vaccines, supporting potential cross-vaccine platform applications of these markers for guiding decisions about vaccine approval and use. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Huang, Yunda |e verfasserin |4 aut | |
| 700 | 1 | |a Benkeser, David |e verfasserin |0 (orcid)0000-0002-1019-8343 |4 aut | |
| 700 | 1 | |a Carpp, Lindsay N. |e verfasserin |0 (orcid)0000-0003-0333-5925 |4 aut | |
| 700 | 1 | |a Áñez, Germán |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Wayne |e verfasserin |4 aut | |
| 700 | 1 | |a McGarry, Alice |e verfasserin |4 aut | |
| 700 | 1 | |a Dunkle, Lisa M. |e verfasserin |4 aut | |
| 700 | 1 | |a Cho, Iksung |e verfasserin |4 aut | |
| 700 | 1 | |a Houchens, Christopher R. |e verfasserin |4 aut | |
| 700 | 1 | |a Martins, Karen |e verfasserin |4 aut | |
| 700 | 1 | |a Jayashankar, Lakshmi |e verfasserin |4 aut | |
| 700 | 1 | |a Castellino, Flora |e verfasserin |4 aut | |
| 700 | 1 | |a Petropoulos, Christos J. |e verfasserin |0 (orcid)0000-0001-5496-8090 |4 aut | |
| 700 | 1 | |a Leith, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Haugaard, Deanne |e verfasserin |4 aut | |
| 700 | 1 | |a Webb, Bill |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yiwen |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Chenchen |e verfasserin |4 aut | |
| 700 | 1 | |a Borate, Bhavesh |e verfasserin |4 aut | |
| 700 | 1 | |a van der Laan, Lars W. P. |e verfasserin |4 aut | |
| 700 | 1 | |a Hejazi, Nima S. |e verfasserin |4 aut | |
| 700 | 1 | |a Randhawa, April K. |e verfasserin |4 aut | |
| 700 | 1 | |a Andrasik, Michele P. |e verfasserin |4 aut | |
| 700 | 1 | |a Kublin, James G. |e verfasserin |4 aut | |
| 700 | 1 | |a Hutter, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Keshtkar-Jahromi, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Beresnev, Tatiana H. |e verfasserin |4 aut | |
| 700 | 1 | |a Corey, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Neuzil, Kathleen M. |e verfasserin |4 aut | |
| 700 | 1 | |a Follmann, Dean |e verfasserin |4 aut | |
| 700 | 1 | |a Ake, Julie A. |e verfasserin |4 aut | |
| 700 | 1 | |a Gay, Cynthia L. |e verfasserin |4 aut | |
| 700 | 1 | |a Kotloff, Karen L. |e verfasserin |4 aut | |
| 700 | 1 | |a Koup, Richard A. |e verfasserin |4 aut | |
| 700 | 1 | |a Donis, Ruben O. |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Peter B. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-022-35768-3 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.06.22.22276362 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||